ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares
LEIDEN, The Netherlands (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the pricing of its previously announced underwritten public offering and concurrent registered direct offering of its ordinary shares at a price to the public of $3.25 per share. All of the shares are being offered by ProQR. In addition, in the public offering, ProQR has granted the underwriters a 30-day option to purchase up to 745,471 additional ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds from both offerings are expected to be approximately $20 million, assuming no exercise of the underwriters’ option to purchase additional shares in the public offering.
H.C. Wainwright & Co. is acting as sole book-running manager for the offering. National Securities Corporation is acting as co-manager for the offering.
The pricing for the underwritten public offering was for a total of 4,969,805 ordinary shares for expected gross proceeds of $16.15 million. The pricing for the concurrent registered direct offering was for a total of 1,427,692 ordinary shares for expected gross proceeds of $4.64 million. The offerings are expected to close on November 16, 2017, subject to customary closing conditions. In addition, closing of the registered direct offering is contingent upon ProQR completing the public offering. The registered direct offering was made without an underwriter or a placement agent.
A shelf registration statement relating to the offered ordinary shares was filed with the Securities and Exchange Commission (SEC) on October 2, 2015, which was declared effective on October 19, 2015. A preliminary prospectus supplement related to the underwritten public offering has been filed with the SEC and is available on the SEC's website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to each offering may be obtained from H.C. Wainwright & Co., LLC at 430 Park Avenue, 4th Floor, New York, New York 10022, or by e-mail: firstname.lastname@example.org or by telephone: 646-975-6996.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.